Median in Biological Technology

Sunesis Reports Financial Results for the Second Quarter 2009

... disease for 12 weeks or more. The preliminary median progression free survival (PFS) for each of the ... days, and 109 days, respectively. The preliminary median PFS for the 44 women who were both platinum ... is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... Two Cohorts Have Met or Exceeded the Expected median Survival Time for Recurrent GBM Patients - ... have all either met or exceeded the expected median survival time of six months for recurrent GBM ... glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... an overall response rate of 57 percent with a median duration of response of 8.5 months. The median time to progression in this cohort has not been ... 18 percent achieved partial responses and the median duration of response has not yet been reached in ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... Survival even though data not fully mature with median 8.1 month vs. 6.9 month; p=0.544 ... Prognostic Index score (>=2). The median prior doxorubicin equivalent dose was ... four or more cycles of therapy compared to a median of three cycles in the comparator arm. ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... response rate, survival rate at 30 months, median progression-free survival and median overall survival. A combined group analysis of ... median Progression Free Survival (Months) ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... with advanced prostate cancer: 1) The median overall survival in patients with advanced ... available at www.oncogenex.com . "A 6.9 month median overall survival difference would represent a ... to the survival results presented and based on a median follow-up of 32 months, data were presented as ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding ... (>99%) at all dose levels. At 200 mg bid, the median viral load reduction was 2.4 log10 (range of 0.4 ... 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... updates are needed before a mature median survival for the OGX-011 arm can be ... OncoGenex has calculated that the final median survival for patients in the OGX-011 arm ... months, representing at least a 5.8 month median survival benefit. For comparison, docetaxel was ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival ... chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival ... for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months ...

REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

... in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... to standard induction chemotherapy. Data on the median duration of response for patients achieving a CR ... days or more or a complete or partial response. median progression free survival is 82 days. All ... is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 ...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

... the three dose levels. The Canadian cohort had a median survival of 13.8 months, which compares very ... develop brain metastases. In recent studies, the median survival of patients with brain metastases, most ... treated with the combination had a mean and median survival of 7.32 and 7.00 months respectively ...

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... First-line trial currently shows median overall survival of 27.5 months for OGX-011 ... resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel ...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

... mg dose and 0.666 for the 600 mg dose). The median time to alleviation of symptoms was 59.1 ... for all groups combined, the study demonstrated a median of 25.3 hours to clinical stability, a median of 2.0 log reduction in time weighted change ...

BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza

... for all groups combined, the study demonstrated a median of 25.3 hours to clinical stability, a median of 2.0 log reduction in time weighted change from ... titer, zero mortality, no clinical relapse and a median of 10.8 days of time to resumption of usual ...

OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011

... based on previously published reports: With a median follow-up of 17.2 months following the start of second-line chemotherapy, median survival has been estimated at 11.4 months in ... favorably with published results reporting median survivals at approximately 10 months for HRPC ...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

... 64 percent experienced a complete response with a median estimated time to progression (TTP) of 14 months. ... 57 percent and 46 percent, respectively. median time to progression for these patients was 11 ... were 86 percent and 64 percent, respectively. median time to progression for this subset of patients ...

NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING

... response. The primary endpoint for the trial is median progression free survival at six months after ... described preliminary results including that the median progression free survival was 5.9 months, that ... (2 Complete Responses, 6 Partial Responses) and median survival time was 7.2 months. Results also ...

YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING

... for chemotherapy-containing regimens. "The median survival of 60 weeks in the palliative setting ... (J Clin. Oncol. 2004 Mar 1;22(5):801-10), the median survival in that patient population was reported ... radiation in "good risk" patients resulted in a median overall survival of 11.4 and 12.3 months ...

Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma

... low-grade B-cell NHL patients, who had received a median of three prior regimens, were treated with ... three patients achieved a partial response (PR). median time to progression (TTP) was estimated to ... patients with relapsed or refractory NHL. With a median follow up of 11 months, results from the first ...

DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance

... the LifeScience100 was vastly different, with a median total shareholder return of 14.4% last year. CEO ... several encouraging results. In the Tech100, median target bonuses for the Top 20 ... ($1.4M), whereas in the Bottom 20 companies, median target bonuses were 150% of base salary, and ...

Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting

... patients with higher HER2 expression levels had a median time to progression of 11.6 months while those in the lower half of the distribution had a median time to progression of 5.4 months. This was also ... with higher levels of HER2 homodimers who had a median time to progression of 11.6 months compared to ...

C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study

... patients receiving C1-INH concentrate had a median time to symptom relief of 30 minutes, versus 90 ... exhibited a highly significant reduction in the median time to onset of HAE symptom relief (30 ... resolution of all symptoms, and safety. The median time to the onset of relief was less than 33 ...

OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

... chemotherapy: Patients received a median of 6 cycles of mitoxantrone or 7.5 cycles of ... favorably with published reports documenting a median of 3-4 cycles with second-line chemotherapy ... on previously published reports: With a median follow-up of 13.3 months following second-line ...

Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

... assessment on the study's primary endpoint of median survival. These preliminary results demonstrated ... arm, with approximately a 40% improvement in median survival noted between the curves. ... for TARGET, based on the primary endpoint of median survival, is expected to be available in the ...

EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study

... tumor patients. The current analysis includes median follow up time over 8 months. median progression-free survival and overall survival ... patients have remained on treatment. Once the median progression free survival is established, we will ...

UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients

... placebo over the 12-week treatment period. The median reduction in seizure frequency from baseline ... with partial onset seizures, finding that the median percent reduction in seizure frequency across all ... duration of exposure. A small increase in median PR interval (5 to 9 msec) across all subjects ...

Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients

... once daily may have the potential to increase the median overall survival time for men with asymptomatic ... who received ZD4054 10 mg once daily had a median OS of 24.5 months, patients who received ZD4054 15 mg once daily had a median OS of 23.5 months and the placebo arm had ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did ... free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a ...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

... regimens improved the overall response rate, survival rate at 30 months, median progression-free survival and median overall survival. A combined group analysis of the nimotuzumab arms vs. ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

... planned. Key results compared to published clinical data: - median survival three times longer (5.5 months vs. 1.5 months) - Remission ... (Houston, TX, USA) (published by Giles et al, Cancer 2005;104:547-54). median overall survival in the elacytarabine study was an impressive three times ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ... treatment period according to RECIST criteria. Recent analysis shows the median progression free survival of the patients enrolled in the first part of ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the ... divided into chemo-sensitive (A) and chemo refractory (B) cohorts. median time to progression was 17.4 weeks (range 5.3 - 36.1 weeks) in A and 11.7 ...

Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results

... of infectious diarrhea. The trial achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). median TLUS for patients treated with prulifloxacin was 32.8 hours which was ...

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

... therapy, demonstrated that patients treated with picoplatin showed a median overall survival of 27 weeks(1). Historical data indicates that BSC treatment of patients with recurrent SCLC have a median overall survival of 14 weeks(2). Based on patient enrollment data, the ...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... (ribavirin). After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage ... receiving the combination of ITMN-191 and R7128 for 14 days experienced a median reduction in viral levels of -4.8 to -5.2 Log10 IU/mL in the last two ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

... been followed for at least six months since their initial treatment, the median progression-free survival (PFS) is currently six months, while the overall ... refractory patients typically have a PFS of approximately two months and a median survival ranging from 4.5 to 6.5 months. The overall survival figure may ...

Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients

... of these patients, LVEF recovered to greater than or equal to 50% after a median time of nine weeks (range, 3-38 weeks). In the remaining patients, LVEF ... the highest reported in HER-2-overexpressing breast cancer patients. The median time to progression was not reached in patients with locally advanced ...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

... that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year ... diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than ...

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

... two divided doses. The primary endpoints of the studies were the median percent reduction in seizure frequency per 28 days from the baseline to ... with increasing Vimpat(R) doses vs. 0.9 percent for placebo) and also for median increase in percentage of seizure-free days (7.4 percent, 9.3 percent, and ...